The Checkup by Singlecare

AUGUST 8, 2024

A medication shortage occurs when the demand for a drug is greater than the supply, according to the Food and Drug Administration (FDA). The FDA tracks drug shortages at the national level by obtaining information from drug manufacturers about their ability to produce medications. Many factors cause medication shortages.

Compounding 52

Compounding FDA Compounding Pharmacies Community Pharmacies 52

European Pharmaceutical Review

JANUARY 3, 2023

Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers, yet they can cause ototoxicity, permanent and irreversible hearing loss, which occurs in up to 50-60 percent of adult patients and 90 percent of paediatric patients who survive cancer. This control arm will provide natural history data.

Chemotherapy 52

Chemotherapy Compounding FDA 52

pharmaphorum

NOVEMBER 29, 2022

By enabling strong CD8 T-cell infiltration in cold tumor tissues, NT-I7, a compound developed by NeoImmuneTech, is capable of promoting a microenvironment that contributes to clinical efficacy, when combined with a CPI. Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy.

Immunization 105

Immunization Chemotherapy Compounding FDA 105

The Checkup by Singlecare

MARCH 28, 2024

Veterinarians may use it in a cat to prevent nausea and vomiting due to chemotherapy. Pet parents will use tablets made for humans or mirtazapine custom-made by a compounding pharmacy. However, a veterinarian may supply mirtazapine in a liquid format made by a compounding pharmacy. Is mirtazapine safe for dogs?

Dosage 52

Dosage Compounding Pharmacies Compounding Labelling 52

The Checkup by Singlecare

MARCH 23, 2023

Understanding the difference between CBD vs. marijuana Cannabinoids are compounds found in the cannabis plant, Cannabis sativa. The Food and Drug Administration (FDA) approved the drug to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Marijuana , also called cannabis, contains more than 100 cannabinoids.

Controlled Substances 52

Controlled Substances Medical Records Chemotherapy Compounding 52

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Tenapanor : Tenapanor was approved by the FDA in September of 2019 for IBS-C. [45] As the intestines are made of smooth muscles, a reduction in the action of these muscles can slow down digestion and cause constipation. 2020;12(1):205.

Health and Personal Care Stores 84

Health and Personal Care Stores Chemotherapy Immunization Compounding 84

Pharmaceutical Technology

MARCH 23, 2023

The US Food and Drug Administration (FDA) has approved Incyte ’s Zynyz (retifanlimab-dlwr) to treat metastatic or recurrent locally advanced merkel cell carcinoma (MCC) in adult patients. It is also being assessed in other tumour types and along with other Incyte pipeline compounds.

FDA 98

FDA Adverse Reactions Compounding Chemotherapy 98

pharmaphorum

DECEMBER 23, 2020

The FDA has gone on to grant a fast review of the results ahead of a regulatory decision on the new lung cancer indication next year. While Trodelvy is already conditionally approved in the US, the data showing the drug improved overall survival compared with chemotherapy could be enough for it to clinch a permanent licence in the US.

FDA 96

FDA Chemotherapy Compounding Vaccines 96

The FDA Law Blog

JANUARY 18, 2024

Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. HHS forwards FDA’s analysis and recommendation to DEA. By Larry K.

FDA 69

FDA Controlled Substances Chemotherapy Compounding 69

European Pharmaceutical Review

DECEMBER 5, 2022

The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death. The PSMAfore study.

Chemotherapy 105

Chemotherapy Compounding Labelling FDA 105

pharmaphorum

APRIL 20, 2021

The next milestone in Seagen and Astellas’ bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster will come in August, when the FDA concludes an accelerated review of two bladder cancer filings. . Both have been granted an FDA priority review with an action date of 17 August.

Chemotherapy 52

Chemotherapy FDA Compounding Labelling 52

Pharmaceutical Technology

MARCH 29, 2023

AlgoTx remains on track to start enrolling subjects of a Phase II study of its compound ATX01 for the rare condition erythromelalgia in Q2 2023, says CEO Stéphane Thiroloix. In June 2020, the FDA gave ATX01 an orphan drug designation in erythromelalgia.

Chemotherapy 52

Chemotherapy Compounding Communication FDA 52

The FDA Law Blog

FEBRUARY 11, 2024

FDA has not approved marijuana for medical use because no double-blind, published studies show safety and efficacy for raw marijuana. In other words, no rescheduling. There has been no evidence that marijuana’s schedule should change since the last rescheduling review in 2016.

Controlled Substances 59

Controlled Substances Chemotherapy FDA Compounding 59